LB0001 MAVRILIMUMAB IMPROVES OUTCOMES IN PHASE 2 TRIAL IN NON-MECHANICALLY-VENTILATED PATIENTS WITH SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPERINFLAMMATION

L. Pupim; T. S. Wang; K. Hudock; J. Denson; N. Fourie; L. Hercilla Vasquez; K. Luz; M. Madjid; K. Mcharry; J. F. Saraiva; E. Tobar; T. Zhou; M. Samant; J. Pirrello; F. Fang; J. F. Paolini; A. Pano; B. C. Trapnell

LB0001 MAVRILIMUMAB IMPROVES OUTCOMES IN PHASE 2 TRIAL IN NON-MECHANICALLY-VENTILATED PATIENTS WITH SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPERINFLAMMATION

Annals of the Rheumatic Diseases (2021) - Comments
doi: 10.1136/annrheumdis-2021-eular.5012 issn: 0003-4967 issn: 1468-2060

L. Pupim, T. S. Wang, K. Hudock, J. Denson, N. Fourie, L. Hercilla Vasquez, K. Luz, M. Madjid, K. Mcharry, J. F. Saraiva, E. Tobar, T. Zhou, M. Samant, J. Pirrello, F. Fang, J. F. Paolini, A. Pano, B. C. Trapnell